title: The Frequency of Medication-related Osteonecrosis of the Jaw and its Associated Risk Factors.
abstract: This article provides the best current frequency estimate of medication-related osteonecrosis of the jaws (MRONJ), and identifies factors associated with the risk of developing osteonecrosis of the jaw (ONJ) among patients exposed to relevant medications (ie, antiresorptive or antiangiogenic agents). MRONJ is a rare but serious complication of cancer treatment or osteoporosis management. This review confirms that antiresorptive medications such as oral or intravenous bisphosphonates and denosumab are the most common risk factors for developing ONJ. The risk of MRONJ is greater in patients with cancer than in those receiving antiresorptive treatments for osteoporosis by a factor of 10.
authors.affiliation: Department of Oral and Maxillofacial Surgery, University of Washington School of Dentistry, 1959 Northeast Pacific Street, Health Sciences Building B-241, Box 357134, Seattle, WA 98195-7134, USA. Electronic address: tbdodson@uw.edu.
authors.forename: Thomas B
authors.initials: TB
authors.lastname: Dodson
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D059266:Bisphosphonate-Associated Osteonecrosis of the Jaw / Q000453:epidemiology; D050071:Bone Density Conservation Agents / Q000009:adverse effects*; D000069448:Denosumab / Q000009:adverse effects*; D004164:Diphosphonates / Q000009:adverse effects*; D006801:Humans; D007571:Jaw Diseases / Q000139:chemically induced* / Q000453:epidemiology*; D009369:Neoplasms / Q000188:drug therapy; D010020:Osteonecrosis / Q000139:chemically induced* / Q000453:epidemiology*; D010024:Osteoporosis / Q000188:drug therapy; D012307:Risk Factors
chemical_list: D020533:Angiogenesis Inhibitors; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D000069448:Denosumab
keywords: Antiangiogenic agents; Antiresorptive medications; Frequency; Medication-related osteonecrosis of the jaws; Oral bisphosphonates; Risk factors; Zolendronate